<SEC-DOCUMENT>0001104659-21-060485.txt : 20210504
<SEC-HEADER>0001104659-21-060485.hdr.sgml : 20210504
<ACCEPTANCE-DATETIME>20210504070845
ACCESSION NUMBER:		0001104659-21-060485
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20210504
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210504
DATE AS OF CHANGE:		20210504

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INCYTE CORP
		CENTRAL INDEX KEY:			0000879169
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				943136539
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12400
		FILM NUMBER:		21885965

	BUSINESS ADDRESS:	
		STREET 1:		1801 AUGUSTINE CUT-OFF
		CITY:			WILMINGTON
		STATE:			DE
		ZIP:			19803
		BUSINESS PHONE:		3024986700

	MAIL ADDRESS:	
		STREET 1:		1801 AUGUSTINE CUT-OFF
		CITY:			WILMINGTON
		STATE:			DE
		ZIP:			19803

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INCYTE CORP
		DATE OF NAME CHANGE:	20030318

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INCYTE GENOMICS INC
		DATE OF NAME CHANGE:	20000710

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INCYTE PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19930902
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2114920d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:incy="http://incyte.com/20210504">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_incy_incyte.com_20210504 -->
<!-- Field: Set; Name: xdx; ID: xdx_04F_20210504_20210504 -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DEntityCentralIndexKey_0000879169 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-05-04to2021-05-04" name="dei:EntityCentralIndexKey">0000879169</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-05-04to2021-05-04" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="incy-20210504.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-05-04to2021-05-04">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-04</xbrli:startDate>
        <xbrli:endDate>2021-05-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM&#160;<span id="xdx_901_edei--DocumentType_c20210504__20210504_z0ZMTangMIOf"><ix:nonNumeric contextRef="From2021-05-04to2021-05-04" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section&#160;13 or 15(d)&#160;of
the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):&#160;
<span id="xdx_906_edei--DocumentPeriodEndDate_c20210504__20210504_z6Jvpp4RS028"><ix:nonNumeric contextRef="From2021-05-04to2021-05-04" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">May 4, 2021</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_901_edei--EntityRegistrantName_c20210504__20210504_zf8nbnKK1N2c"><ix:nonNumeric contextRef="From2021-05-04to2021-05-04" name="dei:EntityRegistrantName">INCYTE CORPORATION</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: top; width: 34%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_904_edei--EntityIncorporationStateCountryCode_c20210504__20210504_zNoocl61k57a"><ix:nonNumeric contextRef="From2021-05-04to2021-05-04" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span><br />
(State or Other Jurisdiction of<br /> Incorporation)</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90D_edei--EntityFileNumber_c20210504__20210504_zBKbRgLZNbB6"><ix:nonNumeric contextRef="From2021-05-04to2021-05-04" name="dei:EntityFileNumber">001-12400</ix:nonNumeric></span></b></span><br />
(Commission File Number)</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90C_edei--EntityTaxIdentificationNumber_c20210504__20210504_zpactugaDAHf"><ix:nonNumeric contextRef="From2021-05-04to2021-05-04" name="dei:EntityTaxIdentificationNumber">94-3136539</ix:nonNumeric></span></b></span><br />
(I.R.S. Employer<br /> Identification No.)</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: top; width: 50%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90F_edei--EntityAddressAddressLine1_c20210504__20210504_zqK4iE8frsPd"><ix:nonNumeric contextRef="From2021-05-04to2021-05-04" name="dei:EntityAddressAddressLine1">1801 Augustine Cut-Off</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 49%; text-align: center">&#160;</td></tr>
<tr>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_903_edei--EntityAddressCityOrTown_c20210504__20210504_zlswuHj5EhHd"><ix:nonNumeric contextRef="From2021-05-04to2021-05-04" name="dei:EntityAddressCityOrTown">Wilmington</ix:nonNumeric></span>, <span id="xdx_909_edei--EntityAddressStateOrProvince_c20210504__20210504_zvDBDby1hWxk"><ix:nonNumeric contextRef="From2021-05-04to2021-05-04" name="dei:EntityAddressStateOrProvince">DE</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_909_edei--EntityAddressPostalZipCode_c20210504__20210504_zIZef1KzNl12"><ix:nonNumeric contextRef="From2021-05-04to2021-05-04" name="dei:EntityAddressPostalZipCode">19803</ix:nonNumeric></span></b></span></td></tr>
<tr>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Address of principal executive offices)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Zip Code)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_90C_edei--CityAreaCode_c20210504__20210504_zfsa1fGNIhtj"><ix:nonNumeric contextRef="From2021-05-04to2021-05-04" name="dei:CityAreaCode">302</ix:nonNumeric></span>) <span id="xdx_903_edei--LocalPhoneNumber_c20210504__20210504_zg7CXtwVmoS8"><ix:nonNumeric contextRef="From2021-05-04to2021-05-04" name="dei:LocalPhoneNumber">498-6700</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s telephone number,<br />
including area code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>N/A</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form&#160;8-K filing
is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-indent: -13.5pt"><span style="font-family: Wingdings"><span id="xdx_90F_edei--WrittenCommunications_c20210504__20210504_zgv5crnJyM75"><ix:nonNumeric contextRef="From2021-05-04to2021-05-04" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;
</span>Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-indent: -13.5pt"><span style="font-family: Wingdings"><span id="xdx_90B_edei--SolicitingMaterial_c20210504__20210504_zrNZb0rVuBJ3"><ix:nonNumeric contextRef="From2021-05-04to2021-05-04" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;
</span>Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-indent: -13.5pt"><span style="font-family: Wingdings"><span id="xdx_900_edei--PreCommencementTenderOffer_c20210504__20210504_zyT7gcJpFWrf"><ix:nonNumeric contextRef="From2021-05-04to2021-05-04" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;
</span>Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-indent: -13.5pt"><span style="font-family: Wingdings"><span id="xdx_90F_edei--PreCommencementIssuerTenderOffer_c20210504__20210504_za2T8ZSL8Lu2"><ix:nonNumeric contextRef="From2021-05-04to2021-05-04" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;
</span>Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240-13e-4(c))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Securities registered pursuant to Section&#160;12(b)&#160;of
the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Title&#160;of&#160;each&#160;class</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 34%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Trading&#160;symbol(s)&#160;</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered</b></span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_edei--Security12bTitle_c20210504__20210504_zJITaEFPWRY2"><ix:nonNumeric contextRef="From2021-05-04to2021-05-04" name="dei:Security12bTitle">Common Stock, $.001 par value per share</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_edei--TradingSymbol_c20210504__20210504_zocTT8czEkE3"><ix:nonNumeric contextRef="From2021-05-04to2021-05-04" name="dei:TradingSymbol">INCY</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_edei--SecurityExchangeName_c20210504__20210504_zqlNTpms9ase"><ix:nonNumeric contextRef="From2021-05-04to2021-05-04" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The Nasdaq Stock Market LLC</ix:nonNumeric></span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt">Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule&#160;12b&#8211;2
of the Securities Exchange Act of 1934 (&#167; 240.12b&#8211;2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="margin: 0pt 0 0pt 13.5pt; text-align: right; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Emerging
growth company&#160;&#160; <span style="font-family: Wingdings"><span id="xdx_90F_edei--EntityEmergingGrowthCompany_c20210504__20210504_zNq9AdYxzOql"><ix:nonNumeric contextRef="From2021-05-04to2021-05-04" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="margin: 0pt 0 0pt 13.5pt; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange
Act.&#160; <span style="font-family: Wingdings">&#168;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 1in"><b>Item 2.02</b></td>
    <td><b>Results of Operations and Financial Condition.</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On May 4, 2021, Incyte Corporation issued a press
release announcing financial results for its first fiscal quarter ended March 31, 2021. The full text of the press release is furnished
as Exhibit&#160;99.1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 1in"><b>Item &#160;9.01</b></td>
    <td><b>Financial Statements and Exhibits. </b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.5in; text-align: left">(d)</td>
    <td style="text-align: justify"><b>Exhibits</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 1in">&#160;</td>
    <td style="width: 0.5in; text-align: left"><a href="tm2114920d1_ex99-1.htm" style="-sec-extract: exhibit">99.1</a></td>
    <td style="text-align: justify"><a href="tm2114920d1_ex99-1.htm" style="-sec-extract: exhibit">Press release issued by Incyte Corporation dated May 4, 2021.</a></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 1in">&#160;</td>
    <td style="width: 0.5in; text-align: left">104</td>
    <td style="text-align: justify">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#160;</p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>SIGNATURE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Dated: May 4, 2021</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font: 10pt Times New Roman, Times, Serif">INCYTE CORPORATION</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 48%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">By: </span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">/s/ Christiana Stamoulis</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Christiana Stamoulis</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Executive Vice President and Chief Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p></div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p>

<p style="margin: 0pt 0">&#160;</p>



<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>









</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5Fk3rH/ZNi4pYRYqIr9FuJdhmyyb+HclbGlvEZWFZZr4ZITpiSQtdIsNxlqWwx6oulUPIsEBGc0bvSFbrGPzN8KKtY2Vc8/7AhDyDnhl25enshcZ61xbzGOS415e9cAJyEMsRTDci+OoJmULnaJxWJSiTw46pZo1O8atN2KsnGapeTdUB2WoyMYRd2cpviGQYwZbu6kF8tZCmiQg6zQRiyXSrvzU366iCeYmV77It+t/gAzMoSW8= -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2114920d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

                           <P STYLE="margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0; text-indent: 3in">Exhibit 99.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2114920d1_ex99-1img001.jpg" ALT=""><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>FOR IMMEDIATE RELEASE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Incyte Reports 2021 First Quarter Financial
Results<BR>
and Provides Updates on Key Clinical Programs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 13.5pt"><FONT STYLE="font-family: Symbol">-</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Total product and royalty revenues of $605 million in Q1 2021 (+6% vs
Q1</I></FONT><I>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">2020) </FONT></I></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 13.5pt"><FONT STYLE="font-family: Symbol">-</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Jakafi<SUP>&reg;</SUP> (ruxolitinib) revenues of $466 million in Q1</I></FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><I>2021
(+1% vs Q1</I></FONT><I>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">2020); reaffirming full year guidance of $2.125-$2.20
billion</FONT></I></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 13.5pt"><FONT STYLE="font-family: Symbol">-</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Pemazyre<SUP>&reg;</SUP> (pemigatinib) now also approved in Europe and
Japan, becoming the first internally discovered product to be globally commercialized by Incyte</I></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 13.5pt"><FONT STYLE="font-family: Symbol">-</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Three regulatory submissions accepted by the FDA for Priority
                                                                                                       Review, including potential approval of ruxolitinib cream in the U.S. for atopic dermatitis in June</I></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Conference Call and Webcast Scheduled Today at
8:00 a.m. EDT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>WILMINGTON, Del. &ndash; May 4, 2021</B> &ndash; Incyte (Nasdaq:
INCY) today reports 2021 first quarter financial results, and provides a status update on the Company&rsquo;s development portfolio.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;In the first quarter, we continued to make significant progress
in our strategy to drive growth and diversification. While Jakafi<SUP>&reg;</SUP> (ruxolitinib) net sales were affected by typical seasonal
effects and softer patient demand growth due to the ongoing pandemic, we remain confident in our full-year outlook. We are already seeing
a return of new patient starts to pre-COVID levels and are excited for the potential launch in steroid-refractory chronic graft-versus-host
disease (GVHD) later this year. The launches of Monjuvi<SUP>&reg;</SUP> (tafasitamab) and Pemazyre<SUP>&reg;</SUP> (pemigatinib) continue
to progress with good uptake by both academic and community physicians,&rdquo; stated Herv&eacute; Hoppenot, Chief Executive Officer,
Incyte. &ldquo;We expect an exciting year ahead for Incyte with the potential for multiple approvals, including ruxolitinib cream in
atopic dermatitis, and several regulatory filings, notably parsaclisib in NHL and ruxolitinib cream in vitiligo. We are also initiating
pivotal trials across key development programs for both tafasitamab and LIMBER this year.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Portfolio Update</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>MPNs and GVHD &ndash; key highlights</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Ruxolitinib in GVHD:</B> The supplemental New Drug Application (sNDA)
seeking approval of ruxolitinib for the treatment of steroid-refractory chronic GVHD has been accepted for Priority Review by the U.S.
Food and Drug Administration (FDA); the Prescription Drug User Fee Act (PDUFA) date is June 22, 2021. The application for approval was
based on the successful randomized REACH3 trial comparing ruxolitinib with best available therapy (BAT).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>LIMBER: </B>Our <B>L</B>eadership <B>I</B>n <B>M</B>PNs <B>BE</B>yond
<B>R</B>uxolitinib (LIMBER) development program continues to progress with once daily (QD) ruxolitinib in stability testing, and multiple
ongoing and planned combination trials with ruxolitinib on track. Both monotherapy trials of INCB57643 (BET) and INCB00928 (ALK2) are
ongoing, and combination trials of both agents with ruxolitinib in patients with myelofibrosis (MF) are expected to initiate later this
year. Two Phase 3 trials of ruxolitinib in combination with parsaclisib as a first-line therapy for patients with MF (LIMBER-313) and
as a therapy for MF patients with a suboptimal response to ruxolitinib monotherapy (LIMBER-304) are ongoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">Indication and status</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 50%; text-align: left">Once-a-day ruxolitinib <BR> (JAK1/JAK2)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: left"><P STYLE="margin-top: 0; margin-bottom: 0">Myelofibrosis, polycythemia vera &amp; GVHD: clinical pharmacology studies</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><P STYLE="margin-top: 0; margin-bottom: 0">ruxolitinib
+<BR>
parsaclisib <BR> (JAK1/JAK2 + PI3K&#948;)</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left">Myelofibrosis: Phase 3 (first-line therapy) (LIMBER-313)  <BR>Myelofibrosis: Phase 3 (suboptimal responders to ruxolitinib) (LIMBER-304)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">ruxolitinib + INCB57643<BR> (JAK1/JAK2 + BET)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left">Myelofibrosis: Phase 2 in preparation</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">ruxolitinib + INCB00928 <BR> (JAK1/JAK2 + ALK2)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left">Myelofibrosis: Phase 2 in preparation</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">itacitinib <BR> (JAK1)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left">Myelofibrosis: Phase 2 (low platelets)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ruxolitinib + CK0804<SUP>1</SUP><BR> (JAK1/JAK2 + CB-Tregs)</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left">Myelofibrosis: PoC in preparation</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><P STYLE="margin-top: 0; margin-bottom: 0">ruxolitinib <BR> (JAK1/JAK2)</P>
                                                              <P STYLE="margin-top: 0; margin-bottom: 0"></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steroid-refractory chronic GVHD<SUP>2</SUP>: sNDA under Priority Review</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><P STYLE="margin-top: 0; margin-bottom: 0">itacitinib <BR> (JAK1)</P>
                                                              <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Treatment-na&iuml;ve chronic GVHD: Phase 3 (GRAVITAS-309) <BR>&nbsp; <BR>&nbsp; <BR></TD></TR>
  </TABLE>

<P STYLE="margin: 0"></P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">1)</TD><TD STYLE="text-align: justify">Development collaboration with Cellenkos, Inc.</TD>
</TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">2)</TD><TD STYLE="text-align: justify">Clinical development of ruxolitinib in GVHD conducted in collaboration
with Novartis</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Other Hematology/Oncology &ndash; key highlights</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Tafasitamab:</B> Incyte and MorphoSys strategy to evaluate
tafasitamab as a backbone therapy in multiple combinations for the treatment of various B-cell malignancies is underway. The Phase 3 <I>inMIND</I>
trial, evaluating tafasitamab in combination with lenalidomide plus rituximab (R<SUP>2</SUP>) versus R<SUP>2</SUP> in patients with
follicular lymphoma and marginal zone lymphoma is ongoing. Preparations are underway for the Phase 3 <I>frontMIND</I> trial
evaluating tafasitamab plus lenalidomide in addition to rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone
(R-CHOP) compared to R-CHOP alone as a first-line treatment for patients with newly diagnosed diffuse-large B-cell lymphoma (DLBCL).
A proof-of-concept trial evaluating tafasitamab plus parsaclisib (<I>topMIND</I>) is expected to start later this year and a second
proof-of-concept trial with tafasitamab plus lenalidomide in addition to plamotamab  is expected to start later this year or early next.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Pemigatinib:</B> In March, Pemazyre<SUP>&reg;</SUP> (pemigatinib)
was approved by the Japanese Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with unresectable biliary tract
cancer (BTC) with a fibroblast growth factor receptor 2 (FGFR2) fusion gene, worsening after cancer chemotherapy. Additionally, the European
Commission (EC) approved Pemazyre for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast
growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy. The upcoming
launches in Europe and Japan along with the continued launch in the U.S., signifies the first internally discovered product to be globally
commercialized by Incyte. The Phase 2 tumor agnostic study of pemigatinib is ongoing and continues to enroll well.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Retifanlimab: </B>In March, the Marketing Authorization Application
(MAA) seeking approval of retifanlimab in squamous cell carcinoma of the anal canal (SCAC) was validated by the European Medicines Agency
(EMA). This follows the Biologics License Application (BLA) acceptance by the FDA for the same indication earlier this year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">Indication and status</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0">pemigatinib<BR> (FGFR1/2/3)</P>
                                                                                                                    <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                                                                    <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                                                                    <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                                                                    <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: left">CCA: Phase 2 (FIGHT-202), Phase 3 (FIGHT-302) <BR>&nbsp; <BR>8p11 MPN: Phase 2 (FIGHT-203) <BR>&nbsp; <BR>Tumor agnostic: Phase 2 (FIGHT-207) <BR>&nbsp; <BR>&nbsp; <BR></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>tafasitamab</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(CD19)<SUP>1</SUP></B></P>
                                                                                                                                                                                                                  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
                                                                                                                                                                                                                  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
                                                                                                                                                                                                                  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
                                                                                                                                                                                                                  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
                                                                                                                                                                                                                  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
                                                                                                                                                                                                                  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
                                                                                                                                                                                                                  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
                                                                                                                                                                                                                  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
                                                                                                                                                                                                                  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
                                                                                                                                                                                                                  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
                                                                                                                                                                                                                  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">r/r DLBCL: Phase 2 (L-MIND); Phase 3 (B-MIND); MAA under review</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1L
                                            DLBCL: Phase 1b (<I>firstMIND</I>); Phase 3 (<I>frontMIND</I>) in preparation</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">r/r
                                            FL and r/r MZL: Phase 3 (<I>inMIND</I>)</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">r/r
                                            B-cell malignancies: PoC (<I>topMIND</I>) with parsaclisib (PI3K&#948;) in preparation</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">r/r B-cell malignancies: PoC with lenalidomide and plamotamab in preparation<SUP>2</SUP></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0">parsaclisib
<BR> (PI3K&#948;)</P>
                                                                                                        <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">r/r FL: Phase 2 (CITADEL-203) <BR>&nbsp; <BR>r/r MZL: Phase 2 (CITADEL-204) <BR>&nbsp; <BR>r/r MCL: Phase 2 (CITADEL-205)<BR> r/r FL and r/r MZL: Phase 3 (CITADEL-302) in preparation<BR> 1L MCL: Phase 3 (CITADEL-310) in preparation <BR>&nbsp; <BR>&nbsp; <BR></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>retifanlimab <BR> (PD-1)<SUP>3</SUP></B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">SCAC: Phase 2 (POD1UM-202); Phase 3 (POD1UM-303); BLA and MAA under review <BR>&nbsp; <BR>MSI-high endometrial cancer: Phase 2 (POD1UM-101, POD1UM-204) <BR>&nbsp; <BR>Merkel cell carcinoma: Phase 2 (POD1UM-201) <BR>&nbsp; <BR>NSCLC: Phase 3 (POD1UM-304) <BR>&nbsp; <BR>&nbsp; <BR></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CCA = cholangiocarcinoma; DLBCL = diffuse large B-cell lymphoma; SCAC
= squamous cell anal carcinoma; FL = follicular lymphoma; MZL = marginal zone lymphoma; MCL = mantle cell lymphoma</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">1)</TD><TD>Development of tafasitamab in collaboration with MorphoSys</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">2)</TD><TD>Clinical collaboration with MorphoSys and Xencor, Inc. to investigate the combination of tafasitamab plus lenalidomide in combination
with Xencor&rsquo;s CD20xCD3 XmAb bispecific antibody, plamotamab.</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">3)</TD><TD>retifanlimab licensed from MacroGenics</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Inflammation and Autoimmunity (IAI) &ndash; key highlights</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Dermatology</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Ruxolitinib cream:</B> The NDA seeking approval of ruxolitinib cream
for the treatment of atopic dermatitis <U>(AD) </U>has been accepted for Priority Review by the FDA and the PDUFA date has been set for
June 21, 2021. The application is supported by data from the Phase 3 TRuE-AD clinical trial program - pooled results presented last month
at the American Academy of Dermatology (AAD) virtual conference provided additional context regarding the impact of ruxolitinib cream
on itch relief as well as sleep disturbance and sleep impairment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Also at AAD, Incyte presented 104-week data from the Phase 2
program evaluating ruxolitinib cream in patients with vitiligo. Results showed patients on ruxolitinib cream achieved continued
efficacy through 104 weeks, with a longer duration of treatment being associated with greater levels of repigmentation. Incyte also
presented additional follow-up data which demonstrated a potential for maintenance of repigmentation after discontinuation of
therapy (following  two years of treatment with ruxolitinib cream). The two Phase 3 trials in the TRuE-V program are ongoing with
results expected in Q2&rsquo;21.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>INCB54707:</B> In March, Incyte initiated a Phase 2 trial evaluating
INCB54707 in vitiligo. A Phase 2 trial in hidradenitis suppurativa remains ongoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">Indication and status</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 50%; text-align: left"><P STYLE="margin-top: 0; margin-bottom: 0">ruxolitinib cream<BR> (JAK1/JAK2)</P>
                                                                                            <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: left"><P STYLE="margin-top: 0; margin-bottom: 0">Atopic dermatitis: NDA under Priority Review <BR>&nbsp; <BR>Vitiligo: Phase 3 (TRuE-V1, TRuE-V2; recruitment complete in both trials)</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;<BR></P></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><P STYLE="margin-top: 0; margin-bottom: 0">INCB54707
<BR> (JAK1)</P>
                                                                                   <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Hidradenitis suppurativa: Phase 2b <BR>&nbsp; <BR>Vitiligo: Phase 2 <BR>&nbsp; <BR>&nbsp; <BR></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><P STYLE="margin-top: 0; margin-bottom: 0">parsaclisib
<BR> (PI3K&#948;)</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Autoimmune hemolytic anemia: Phase 2 <BR>&nbsp; <BR>&nbsp; <BR></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">INCB00928<BR> (ALK2)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left">Fibrodysplasia ossificans progressiva: Phase 2 in preparation</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Discovery and early development &ndash; key highlights</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>INCB106385/INCA00186: </B>At AACR, Incyte shared clinical and pre-clinical
data from INCB106385, our novel A2A/A2B adenosine receptor antagonist, and INCA00186, our novel CD73 monoclonal antibody&mdash;both of
which highlight our ongoing efforts targeting the adenosine pathway. Incyte also presented preclinical data for our triplet combination
with retifanlimab, highlighting one of our strategies to overcome adenosine mediated PD-1 suppression.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 50%">Modality</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 49%">Candidates</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><P STYLE="margin-top: 0; margin-bottom: 0">Small molecules</P>
                                                                           <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                           <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">INCB01158 (ARG)<SUP>1</SUP>, INCB81776 (AXL/MER), epacadostat (IDO1), INCB86550 (PD-L1), INCB106385 (A2A/A2B)</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Monoclonal antibodies<SUP>2</SUP></FONT></P>
                                                         <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><P STYLE="margin-top: 0; margin-bottom: 0">INCAGN1876 (GITR), INCAGN2385 (LAG-3), INCAGN1949 (OX40), INCAGN2390 (TIM-3), INCA00186 (CD73)</P>
                                                                           <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;<BR></P></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Bispecific antibodies</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MCLA-145 (PD-L1xCD137)<SUP>3</SUP></FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">1)</TD><TD>INCB01158 development in collaboration with Calithera</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">2)</TD><TD>Discovery collaboration with Agenus</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">3)</TD><TD>MCLA-145 development in collaboration with Merus</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Partnered &ndash; key highlights</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Baricitinib:</B> In April, Incyte and Lilly announced the FDA extended
the review period for the sNDA for baricitinib for the treatment of moderate to severe atopic dermatitis by three months to allow time
for additional data analyses. The PDUFA action date is now expected in early Q3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In March, Incyte and Lilly announced positive results from
BRAVE-AA2 evaluating the efficacy and safety of once-daily baricitinib 2-mg and 4-mg in adults with severe alopecia areata (AA), an
autoimmune disorder that can cause unpredictable hair loss on the scalp, face and other areas of the body. In April, positive
results from a second Phase 3 study, BRAVE-AA1, were announced, with data consistent with the findings from BRAVE-AA2. Lilly plans
to submit an sNDA to the FDA for baricitinib in AA in the second half of 2021. There are currently no FDA-approved therapies for AA,
highlighting the potential for baricitinib to address a significant unmet medical need.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">Indication and status</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; width: 50%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>baricitinib <BR> (JAK1/JAK2)<SUP>1</SUP></B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: left"><P STYLE="margin-top: 0; margin-bottom: 0">Atopic dermatitis: Phase 3 (BREEZE-AD); approved in EU and Japan; sNDA under review <BR>&nbsp; <BR>Severe alopecia areata: Phase 3 (BRAVE-AA1, BRAVE-AA2) <BR>&nbsp; <BR>Systemic lupus erythematosus: Phase 3 (BRAVE I, BRAVE II)</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;<BR></P></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>capmatinib <BR> (MET)<SUP>2</SUP></B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">NSCLC (with MET exon 14 skipping mutations): Approved as Tabrecta in U.S. and Japan <BR>&nbsp; <BR>&nbsp; <BR></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">1)</TD><TD>Worldwide rights to baricitinib licensed to Lilly: approved as Olumiant in multiple territories globally for certain patients with
moderate-to-severe rheumatoid arthritis; approved as Olumiant in EU and Japan for certain patients with atopic dermatitis</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD>2)</TD><TD>Worldwide rights to capmatinib licensed to Novartis</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: s2 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Potential therapies for patients with COVID-19</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Ruxolitinib:</B> In March, Incyte announced results from the Phase
3 DEVENT study assessing ruxolitinib plus standard of care (SoC) versus SoC in patients on mechanical ventilation with COVID-19 associated
Acute Respiratory Disease Syndrome (ARDS). While results indicate a trend towards improvement in mortality in the overall study population,
statistical significance was not reached in the primary endpoint (mortality due to any cause through Day 29). In the U.S. study population
(91% of total study participants), however, there was a clinically and statistically significant improvement in mortality in each of the
5mg and 15mg ruxolitinib arms versus placebo.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Baricitinib: </B>In April, Incyte and Lilly announced the primary
endpoint in the Phase 3 COV-BARRIER study evaluating baricitinib in hospitalized COVID-19 patients - difference in the proportion of participants
progressing to the first occurrence of non-invasive ventilation including high flow oxygen or invasive mechanical ventilation including
extracorporeal membrane oxygenation (ECMO) or death by Day 28) - was not met. There was, however, a 38% reduction in mortality by Day
28 in patients treated with baricitinib in addition to SoC. Lilly will share these data with regulatory authorities in the U.S., European
Union and other geographies to evaluate next steps.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>2021 First Quarter Financial Results</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The financial
measures presented in this press release for the three months ended March 31, 2021 and 2020 have been prepared by the Company in accordance
with U.S. Generally Accepted Accounting Principles (&ldquo;GAAP&rdquo;), unless otherwise identified as a Non-GAAP financial measure.
Management believes that Non-GAAP information is useful for investors, when considered in conjunction with Incyte&rsquo;s GAAP disclosures.
Management uses such information internally and externally for establishing budgets, operating goals and financial planning purposes.
These metrics are also used to manage the Company&rsquo;s business and monitor performance. The Company adjusts, where appropriate, for
expenses in order to reflect the Company&rsquo;s core operations.</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company believes these adjustments are useful to investors by providing an enhanced understanding of the financial performance of the
Company&rsquo;s core operations. The metrics have been adopted to align the Company with disclosures provided by industry peers.</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt -0.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-GAAP
information is not prepared under a comprehensive set of accounting rules</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">and
should only be used in conjunction with and to supplement Incyte&rsquo;s operating results as reported under GAAP. Non-GAAP measures may
be defined and calculated differently by other companies in our industry.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Financial Highlights</U></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Financial Highlights</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">(unaudited, in thousands, except per share amounts)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Three Months Ended</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">March 31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2020</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 74%; text-align: left">Total GAAP revenue</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">604,718</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">568,507</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Total GAAP operating income (loss)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">98,797</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(664,004</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Total Non-GAAP operating income (loss)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">170,303</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(609,480</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">GAAP net income (loss)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">53,535</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(720,642</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Non-GAAP net income (loss)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">148,756</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(618,920</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">GAAP basic EPS</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.24</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(3.33</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Non-GAAP basic EPS</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.68</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(2.86</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">GAAP diluted EPS</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.24</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(3.33</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Non-GAAP diluted EPS</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.67</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(2.86</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Revenue Details</U></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="13" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Revenue Details</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="13" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">(unaudited, in thousands)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Three Months Ended</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">March 31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">%</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Change</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Revenues:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; width: 61%; font: 10pt Times New Roman, Times, Serif; text-align: left">Jakafi net product revenues</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">465,710</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">459,479</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">1</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Iclusig net product revenues</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">25,645</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">27,248</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(6</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Pemazyre net product revenues</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">13,456</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;NM </FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Jakavi product royalty revenues</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">65,602</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">56,333</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">16</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Olumiant product royalty revenues</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">32,258</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">25,447</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">27</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Tabrecta product royalty revenues</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,047</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;NM </FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Product and royalty revenues</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">604,718</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">568,507</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total GAAP revenues</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">604,718</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">568,507</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">NM = not meaningful</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Product and Royalty Revenues</B> Product and royalty revenues for
the quarter ended March 31, 2021 increased 6% over the prior year comparative period as a result of increases in Jakafi net product revenues,
the launch of Pemazyre and higher product royalty revenues from Jakavi and Olumiant. The year-over-year growth rate in Jakafi net product
revenues was impacted by a decline in new patient starts due to the COVID-19 pandemic, and higher patient demand and channel inventory
stocking in the prior year comparative period, due to concerns  over potential  COVID-19 related supply disruptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Operating Expenses</U></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="13" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Operating Expense Summary</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="13" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">(unaudited, in thousands)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Three Months Ended</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">March 31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">%</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2020</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Change</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 61%; text-align: left">GAAP cost of product revenues</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">29,220</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">27,319</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">7</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-GAAP cost of product revenues<SUP>1</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">23,596</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">21,710</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">GAAP research and development</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">306,896</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,085,287</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(72</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-GAAP research and development<SUP>2</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">277,022</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,056,574</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(74</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">GAAP selling, general and administrative</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">153,795</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">111,148</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">38</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-GAAP selling, general and administrative<SUP>3</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">123,313</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">97,573</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">26</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">GAAP change in fair value of acquisition-related contingent consideration</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,526</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,627</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(17</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-GAAP change in fair value of acquisition-related contingent consideration<SUP>4</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">GAAP collaboration loss sharing</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10,484</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,130</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;NM </FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Non-GAAP collaboration loss sharing</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10,484</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,130</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;NM </FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>&nbsp;</SUP></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>1.</SUP> Non-GAAP cost of product revenues excludes the amortization
of licensed intellectual property for Iclusig relating to the acquisition of the European business of ARIAD Pharmaceuticals, Inc. and
the cost of stock-based compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>2.</SUP> Non-GAAP research and development expenses exclude the
cost of stock-based compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>3.</SUP> Non-GAAP selling, general and administrative expenses
exclude the cost of stock-based compensation and a legal reserve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>4.</SUP> Non-GAAP change in fair value of acquisition-related
contingent consideration is null.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Research
and development expenses</B></FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">GAAP and Non-GAAP research and development
expense for the quarter ended March 31, 2021 decreased 72% and 74%, respectively, compared to the same period in 2020, primarily due to
upfront consideration of $805 million related to our collaborative agreement with MorphoSys incurred during the quarter ended March 31,
2020. Excluding the impact of upfront consideration and milestones, research and development expense for the quarter ended March 31, 2021
increased approximately 5% compared to the same period in 2020 reflecting costs to support the continued progression of our pipeline of
programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Selling,
general and administrative expenses</B></FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">GAAP and Non-GAAP
selling, general and administrative expenses for the quarter ended March 31, 2021 increased 38% and 26%, respectively, compared to
the same period in 2020, primarily due to expenses related to the establishment of our dermatology commercial organization and
activities to support the potential launch of ruxolitinib cream for the treatment of atopic dermatitis, a $13 million reserve
related to a settlement in principle in connection with the 2018 civil investigative demand from the U.S. Department of Justice, and
the timing of certain expenses. Excluding the impact of the legal reserve, GAAP selling, general and administrative expenses for the
quarter ended March 31, 2021 increased approximately 26% compared to the same period in 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Other Financial Information</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Operating income (loss)</B> GAAP and Non-GAAP operating income (loss)
for the quarter ended March 31, 2021 increased compared to the same period in 2020 primarily due to the decrease in upfront consideration
and milestones related to our collaborative agreements and the growth in product and royalty revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Cash, cash
equivalents and marketable securities position</B></FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">As of March 31,
2021 and December 31, 2020, cash, cash equivalents and marketable securities totaled $2.0 billion and $1.8 billion, respectively. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: s3 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>2021 Financial Guidance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has reaffirmed its full year 2021 financial guidance, as
detailed below. Guidance does not include revenue from any potential new product launches. However, GAAP and Non-GAAP selling, general
and administrative expense guidance for 2021 includes costs to support the potential launches of ruxolitinib cream as a treatment for
atopic dermatitis in the U.S., pemigatinib as a treatment for cholangiocarcinoma in the EU and Japan, and tafasitamab as a treatment for
DLBCL in the EU. The 2021 financial guidance does not include the impact of any potential future strategic transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; width: 57%; border-bottom: Black 1pt solid; padding-bottom: 10pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 2%; border-bottom: Black 1pt solid; padding-bottom: 10pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 29%; border-bottom: Black 1pt solid; padding-bottom: 10pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current</FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%; border-bottom: Black 1pt solid; padding-bottom: 10pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 10%; border-bottom: Black 1pt solid; padding-bottom: 10pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previous</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; padding-bottom: 10pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jakafi net product revenues</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 10pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 10pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2,125 - $2,200 million </FONT></TD>
    <TD STYLE="vertical-align: top; padding-bottom: 10pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 10pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unchanged</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; padding-bottom: 10pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Hematology/Oncology net product revenues</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; padding-bottom: 10pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top; padding-bottom: 10pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$145 - $160 million</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top; padding-bottom: 10pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top; padding-bottom: 10pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unchanged</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; padding-bottom: 10pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GAAP Cost of product revenues</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 10pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 10pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6 &ndash; 7% of net product revenues </FONT></TD>
    <TD STYLE="vertical-align: top; padding-bottom: 10pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 10pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unchanged</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; padding-bottom: 10pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-GAAP Cost of product revenues<SUP>1</SUP></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; padding-bottom: 10pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top; padding-bottom: 10pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 &ndash; 6% of net product revenues&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top; padding-bottom: 10pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top; padding-bottom: 10pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unchanged</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; padding-bottom: 10pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GAAP Research and development expenses</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 10pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 10pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1,350 - $1,390 million </FONT></TD>
    <TD STYLE="vertical-align: top; padding-bottom: 10pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 10pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unchanged</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; padding-bottom: 10pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-GAAP Research and development expenses<SUP>2</SUP></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; padding-bottom: 10pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top; padding-bottom: 10pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1,220 - $1,250 million </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top; padding-bottom: 10pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top; padding-bottom: 10pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unchanged</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; padding-bottom: 10pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GAAP Selling, general and administrative expenses</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 10pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 10pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$735 - $775 million </FONT></TD>
    <TD STYLE="vertical-align: top; padding-bottom: 10pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 10pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unchanged</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1pt solid; padding-bottom: 10pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-GAAP Selling, general and administrative expenses<SUP>3</SUP></FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1pt solid; padding-bottom: 10pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1pt solid; padding-bottom: 10pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$665 - $700 million </FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1pt solid; padding-bottom: 10pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1pt solid; padding-bottom: 10pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unchanged</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>1.</SUP> Adjusted to exclude the amortization of licensed intellectual
property for Iclusig relating to the acquisition of the European business of ARIAD Pharmaceuticals, Inc. and the estimated cost of stock-based
compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>2.</SUP> Adjusted to exclude the estimated cost of stock-based
compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>3.</SUP> Adjusted to exclude the estimated cost of stock-based
compensation and a legal reserve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Conference Call and Webcast Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Incyte will hold a conference call and webcast this morning at 8:00
a.m. ET. To access the conference call, please dial 877-407-3042 for domestic callers or 201-389-0864 for international callers. When
prompted, provide the conference identification number, 13718346.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If you are unable to participate, a replay of the conference call will
be available for 90 days. The replay dial-in number for the United States is 877-660-6853 and the dial-in number for international callers
is 201-612-7415. To access the replay you will need the conference identification number, 13718346.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The conference call will also be webcast live and can be accessed
at <B><U>investor.incyte.com</U></B><U>.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Incyte</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Incyte is a Wilmington, Delaware-based, global biopharmaceutical company
focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary
therapeutics. For additional information on Incyte, please visit <U>Incyte.com</U> and follow <U>@Incyte.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>About Jakafi<SUP>&reg;</SUP></B></FONT><B>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">(ruxolitinib)</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jakafi is a first-in-class JAK1/JAK2 inhibitor approved by the U.S.
FDA for treatment of steroid-refractory acute GVHD in adult and pediatric patients 12 years and older.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jakafi is also indicated for treatment of polycythemia vera (PV) in
adults who have had an inadequate response to or are intolerant of hydroxyurea as well as adults with intermediate or high-risk myelofibrosis
(MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Jakafi is
marketed by Incyte in the United States and by Novartis as Jakavi<SUP>&reg;</SUP></FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">(ruxolitinib)
outside the United States. Jakafi is a registered trademark of Incyte Corporation. Jakavi is a registered trademark of Novartis AG in
countries outside the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Tafasitamab</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting monoclonal
antibody. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab
incorporates an XmAb<SUP>&reg;</SUP> engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism
including antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Monjuvi<SUP>&reg;</SUP> (tafasitamab-cxix) is approved by the U.S.
Food and Drug Administration in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse
large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous
stem cell transplant (ASCT). This indication is approved under accelerated approval based on overall response rate. Continued approval
for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In January 2020, MorphoSys and Incyte entered into a collaboration
and licensing agreement to further develop and commercialize tafasitamab globally. Monjuvi<SUP>&reg;</SUP> is being co-commercialized
by Incyte and MorphoSys in the United States. Incyte has exclusive commercialization rights outside the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A marketing authorization application (MAA) seeking the approval
of tafasitamab in combination with lenalidomide in the EU has been validated by the European Medicines Agency (EMA) and is currently
under review for the treatment of adult patients with relapsed or refractory DLBCL, including DLBCL arising from low grade lymphoma,
who are not candidates for ASCT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tafasitamab is being clinically investigated as a therapeutic option
in B-cell malignancies in a number of ongoing combination trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Monjuvi<SUP>&reg;</SUP> is a registered trademark of MorphoSys AG.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">XmAb<SUP>&reg;</SUP> is a registered trademark of Xencor, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>About Pemazyre<SUP>&reg;</SUP></B></FONT><B>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">(pemigatinib)</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pemazyre is a kinase inhibitor indicated in the United States for the
treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor
receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test<FONT STYLE="font-size: 10pt"><SUP>1</SUP></FONT>.
This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for
this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In Japan, Pemazyre is approved for the treatment of patients with unresectable
biliary tract cancer (BTC) with a fibroblast growth factor receptor 2 (FGFR2) fusion gene, worsening after cancer chemotherapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In Europe, Pemazyre is approved for the treatment of adults with locally
advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed
after at least one prior line of systemic therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pemazyre is a potent, selective, oral inhibitor of FGFR isoforms 1,
2 and 3 which, in preclinical studies, has demonstrated selective pharmacologic activity against cancer cells with FGFR alterations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pemazyre is marketed by Incyte in the United States, Europe and Japan.
Incyte has granted Innovent Biologics, Inc. rights to develop and commercialize pemigatinib in hematology and oncology in Mainland China,
Hong Kong, Macau and Taiwan. Incyte has retained all other rights to develop and commercialize pemigatinib outside of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pemazyre is a trademark of Incyte Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>About Iclusig<SUP>&reg;</SUP></B></FONT><B>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">(ponatinib)
tablets</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Iclusig targets not only native BCR-ABL but also its isoforms that
carry mutations that confer resistance to treatment, including the T315I mutation, which has been associated with resistance to other
approved TKIs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the EU, Iclusig is approved for the treatment of adult patients
with chronic phase, accelerated phase or blast phase chronic myeloid leukemia (CML) who are resistant to dasatinib or nilotinib; who are
intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I
mutation, or the treatment of adult patients with Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant
to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have
the T315I mutation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Incyte has an exclusive license from ARIAD Pharmaceuticals, Inc., since
acquired by Takeda Pharmaceutical Company Limited, to develop and commercialize Iclusig in the European Union and 22 other countries,
including Switzerland, Norway, Turkey, Israel and Russia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Except for
the historical information set forth herein, the matters set forth in this release contain predictions, estimates and other forward-looking
statements, including without limitation statements regarding</FONT> the <FONT STYLE="font-family: Times New Roman, Times, Serif">potential
launch of Jakafi in steroid-refractory chronic GVHD; the potential for multiple approvals, including ruxolitinib cream in atopic dermatitis,
and several regulatory filings, including parsaclisib in NHL and ruxolitinib cream in vitiligo; expectations regarding the initiation
of multiple pivotal trials across key development programs for both tafasitamab and LIMBER; expectations for the timing of the receipt
and presentation of clinical trial results for the Company&rsquo;s and its collaboration partners&rsquo; product candidates, including
ruxolitinib cream for vitiligo; the expected PDUFA action date for baricitinib for atopic dermatitis; the expected sNDA submission date
for baricitinib for alopecia areata; and the Company&rsquo;s reaffirmed financial guidance for 2021 and the expectations underlying such
guidance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These forward-looking statements are based on the Company&rsquo;s current
expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments
in and risks related to: the actual time required by the FDA to review the Company&rsquo;s NDA for approval for ruxolitinib cream in atopic
dermatitis and the Company&rsquo;s sNDA for ruxolitinib in steroid-refractory chronic GVHD and the results of such reviews; further research
and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards
or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects
in accordance with planned schedules; the effects of the COVID-19 pandemic and measures to address the pandemic on the Company&rsquo;s
clinical trials, supply chain and other third-party providers, sales and marketing efforts, and business, development and discovery operations;
determinations made by the FDA and regulatory agencies outside of the United States; the Company's dependence on its relationships with
and changes in the plans of its collaboration partners; the efficacy or safety of the Company&rsquo;s products and the products of the
Company&rsquo;s collaboration partners; the acceptance of the Company&rsquo;s products and the products of the Company&rsquo;s collaboration
partners in the marketplace; market competition; unexpected variations in the demand for the Company&rsquo;s products and the products
of the Company&rsquo;s collaboration partners; the effects of announced or unexpected price regulation or limitations on reimbursement
or coverage for the Company&rsquo;s products and the products of the Company&rsquo;s collaboration partners; sales, marketing, manufacturing
and distribution requirements, including the Company&rsquo;s and its collaboration partners&rsquo; ability to successfully commercialize
and build commercial infrastructure for newly approved products and any additional products that become approved; greater than expected
expenses, including expenses relating to litigation or strategic activities; and other risks detailed from time to time in the Company&rsquo;s
reports filed with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2020.
The Company disclaims any intent or obligation to update these forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"># # #</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Incyte Contacts</U></B></FONT></TD>
    <TD STYLE="width: 25%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 25%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 25%; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 2pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Media</B></FONT></TD>
    <TD STYLE="padding-bottom: 2pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investors</B></FONT></TD>
    <TD STYLE="padding-bottom: 2pt; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Catalina Loveman</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+1 302 498 6171</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christine Chiou</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+1 302 274 4773</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>cloveman@incyte.com</U></FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>cchiou@incyte.com</U></FONT></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 247.5pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 247.5pt; text-align: center"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 247.5pt; text-align: center">&nbsp;</P>

<!-- Field: Split-Segment; Name: s4 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 247.5pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">INCYTE CORPORATION</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">(unaudited, in thousands, except per share amounts)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Three Months Ended</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">March 31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">GAAP</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Revenues:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 74%; text-align: left; text-indent: 20pt">Product revenues, net</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">504,811</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">486,727</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: 20pt">Product royalty revenues</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">99,907</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">81,780</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total revenues</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">604,718</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">568,507</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Costs and expenses:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 20pt">Cost of product revenues (including definite-lived intangible amortization)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">29,220</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">27,319</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 20pt">Research and development</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">306,896</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,085,287</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 20pt">Selling, general and administrative</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">153,795</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">111,148</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 20pt">Change in fair value of acquisition-related contingent consideration</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,526</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,627</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: 20pt">Collaboration loss sharing</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10,484</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,130</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total costs and expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">505,921</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,232,511</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Income (loss) from operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">98,797</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(664,004</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Other income (expense), net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,407</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8,662</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest expense</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(359</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(602</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Unrealized loss on long term investments</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(27,709</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(48,132</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Income (loss) before provision for income taxes</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">69,322</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(704,076</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Provision for income taxes</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">15,787</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">16,566</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net income (loss)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">53,535</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(720,642</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Net income (loss) per share:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Basic</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.24</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(3.33</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Diluted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.24</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(3.33</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Shares used in computing net income (loss) per share:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Basic</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">219,801</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">216,721</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Diluted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">221,876</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">216,721</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">INCYTE CORPORATION</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">CONDENSED CONSOLIDATED BALANCE SHEETS</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">(unaudited, in thousands)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">March 31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">ASSETS</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 74%; text-align: left; text-indent: 10pt">Cash, cash equivalents and marketable securities</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,962,393</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,801,377</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 10pt">Accounts receivable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">397,357</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">481,994</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 10pt">Property and equipment, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">594,670</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">559,625</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 10pt">Finance lease right-of-use assets, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">27,987</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">28,451</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 10pt">Inventory</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">40,379</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">35,973</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 10pt">Prepaid expenses and other assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">113,976</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">103,313</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 10pt">Long term investments</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">202,174</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">222,301</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 10pt">Other intangible assets, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">166,907</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">172,291</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-indent: 10pt">Goodwill</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">155,593</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">155,593</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: 20pt">Total assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,661,436</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,560,918</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 10pt">Accounts payable, accrued expenses and other liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">636,121</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">648,793</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 10pt">Finance lease liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">34,471</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">34,857</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 10pt">Acquisition-related contingent consideration</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">263,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">266,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: 10pt">Stockholders&rsquo; equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,727,844</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,611,268</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: 20pt">Total liabilities and stockholders&rsquo; equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,661,436</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,560,918</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">INCYTE CORPORATION</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">RECONCILIATION OF GAAP NET INCOME (LOSS) TO SELECTED NON-GAAP ADJUSTED INFORMATION</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">(unaudited, in thousands, except per share amounts)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Three Months Ended</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">March 31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 74%; text-align: left">GAAP Net Income (Loss)</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">53,535</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">(720,642</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Adjustments<SUP>1</SUP>:</I></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-cash stock compensation from equity awards (R&amp;D)<SUP>2</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">29,874</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">28,713</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-cash stock compensation from equity awards (SG&amp;A)<SUP>2</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">17,242</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">13,575</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-cash stock compensation from equity awards (COGS)<SUP>2</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">240</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">225</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-cash interest expense related to convertible notes<SUP>3</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">223</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in fair value of equity investments<SUP>4</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">27,709</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">48,132</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization of acquired product rights<SUP>5</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,384</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,384</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in fair value of contingent consideration<SUP>6</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,526</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,627</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal reserve<SUP>7</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">13,240</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax effect of Non-GAAP adjustments<SUP>8</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,994</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,157</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Non-GAAP Net Income (Loss)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">148,756</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(618,920</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0.25in">Non-GAAP net income (loss) per share:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in">Basic</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.68</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(2.86</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in">Diluted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.67</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(2.86</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0.25in">Shares used in computing Non-GAAP net income (loss) per share:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in">Basic</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">219,801</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">216,721</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in">Diluted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">221,876</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">216,721</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>1.</SUP> Included within the Research and development expenses
line item in the Condensed Consolidated Statements of Operations (in thousands) for the three months ended March 31, 2021 and 2020 are
upfront consideration and milestones of $11,500 and $805,532, respectively, related to our collaborative partners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>2.</SUP> As included within the Cost of product revenues (including
definite-lived intangible amortization) line item; the Research and development expenses line item; and the Selling, general and administrative
expenses line item in the Condensed Consolidated Statements of Operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>3.</SUP> As included within the Interest expense line item in
the Condensed Consolidated Statements of Operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>4.</SUP> As included within the Unrealized loss on long
term investments line item in the Condensed Consolidated Statements of Operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>5.</SUP> As included within the Cost of product revenues (including
definite-lived intangible amortization) line item in the Condensed Consolidated Statements of Operations. Acquired product rights of licensed
intellectual property for Iclusig is amortized utilizing a straight-line method over the estimated useful life of 12.5 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>6.</SUP> As included within the Change in fair value of acquisition-related
contingent consideration line item in the Condensed Consolidated Statements of Operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>7.</SUP> As included within Selling, general and administrative
expenses line item in the Condensed Consolidated Statements of Operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>8.</SUP> As included within the Provision for income taxes line
item in the Condensed Consolidated Statements of Operations. Income tax effects of Non-GAAP adjustments are calculated using the applicable
statutory tax rate for the jurisdictions in which the charges are incurred, while taking into consideration any valuation allowances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: red">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: red"></P>


















<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -4.5pt"><FONT STYLE="font-size: 10pt"><SUP>1</SUP></FONT>
Pemazyre<SUP>&reg; </SUP>(pemigatinib) [Package Insert]. Wilmington, DE: Incyte; 2020.</P>



<P STYLE="margin: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt"></P>

<!-- Field: Page; Sequence: 17; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2114920d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2114920d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !4 -<# 2(  A$! Q$!_\0
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M:N%9SO\ #3;27)&HITU&2BDH_1O[+/\ P5L^&W[0?QOT_P#9N^*_P/\ B_\
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MXJVEHRBFI13NHRW<4F]S^B<M;6!PMK/]U'=Q3^Z33\W;1.ZW.<_:-^-7A_\
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MVA6@O]4^!7QU^%'Q:M8NGV?,^I> 6G)](V\9(I!Y'FCC&#7Z\?#/QUH'Q2\
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M_P#;0_9>\;^&/#$'Q@^-NN>+-4\"Z9:>,]+O]*OQXA\ ^!] 3^UM;5?)T?\
MXJ'1M;8H[$10D2@ M&:^HS^Q=\=Q_P $9_\ AC(Z)I'_  OG_A4 \$?V!_;^
MB?V3_:/_  LD^(/*.OC_ (IW']@GS!)M\HN?*#;_ ):_:;?&4;))'EY+8RQ3
M('K_ %YXQTH5HMJX+<1$ANA"Y/;UYQUQVX'3DS'Q-XFS7&2QN+JTO:3XSCQP
M[1:BN*XPITE52YF^50I17+S6>MI([<!X><.9=A5A,-&3_P",1_U.YY2O)\+R
ME.7)M9RYIS?/M=['\[/Q\_X)D?'/XU?L3_L'V/A7Q!H'P[_;%_8;T#PNN@VF
ML:F]_P"%M5U#0[;PZDFCR:YHFP?VTGB7P+X+\2>$O%**QAE6Y2>.-?$EZT/U
M'^SO\9_^"K_C?XN?#[P7^T#^QM\(?@U\+X9->'QD^*.D_%GPUXKB\0_V9X?U
MAM(E\"^"]#^(7B;Q-X;E\2>)(M")'B:?Q6+3PQ)-YPCOB#'^N<WEP2QJL\4
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M;<3VVI:=<1W^GW4;XVLDENK_ "-G*D9&5*G# BO"?C_^R;^SO^U5X8C\*_M
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@ !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>incy-20210504.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.7a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaWBibOdzZR+OYkxtmB4bQl6XyMlGmwp+C3gMp7GgUQL -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:incy="http://incyte.com/20210504" elementFormDefault="qualified" targetNamespace="http://incyte.com/20210504">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://incyte.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="incy-20210504_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="incy-20210504_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>incy-20210504_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.7a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>incy-20210504_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.7a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://incyte.com/role/Cover" xlink:href="incy-20210504.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://incyte.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>tm2114920d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="incy-20210504.xsd" xlink:type="simple"/>
    <context id="From2021-05-04to2021-05-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
        </entity>
        <period>
            <startDate>2021-05-04</startDate>
            <endDate>2021-05-04</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-05-04to2021-05-04">0000879169</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-05-04to2021-05-04">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2021-05-04to2021-05-04">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2021-05-04to2021-05-04">2021-05-04</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2021-05-04to2021-05-04">INCYTE CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-05-04to2021-05-04">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2021-05-04to2021-05-04">001-12400</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-05-04to2021-05-04">94-3136539</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-05-04to2021-05-04">1801 Augustine Cut-Off</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2021-05-04to2021-05-04">Wilmington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-05-04to2021-05-04">DE</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-05-04to2021-05-04">19803</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-05-04to2021-05-04">302</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-05-04to2021-05-04">498-6700</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2021-05-04to2021-05-04">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2021-05-04to2021-05-04">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2021-05-04to2021-05-04">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2021-05-04to2021-05-04">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2021-05-04to2021-05-04">Common Stock, $.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2021-05-04to2021-05-04">INCY</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2021-05-04to2021-05-04">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-05-04to2021-05-04">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139862342232696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  04,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-12400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INCYTE CORPORATION<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000879169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3136539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1801 Augustine Cut-Off<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Wilmington<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">498-6700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $.001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INCY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MCMQC)8QQ8K3^-8+)#^Q^ %!+ P04    "  5.:12JL0B%C,!   B @  #P
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M2P$"% ,4    "  5.:122WLD]N\    K @  $0              @ &O
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  5.:12F5R<(Q &  "<)P
M$P              @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( !4YI%*,7#"Q,P0  "\0   8              " @0X(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  5.:12GZ ;\+$"  #B#
M#0              @ %W#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( !4Y
MI%*7BKL<P    !,"   +              "  5,/  !?<F5L<R\N<F5L<U!+
M 0(4 Q0    ( !4YI%*JQ"(6,P$  "("   /              "  3P0  !X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  5.:12)!Z;HJT   #X 0  &@
M            @ &<$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    "  5.:1299!YDAD!  #/ P  $P              @ &!$@  6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #+$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2114920d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://incyte.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm2114920d1_8k.htm">tm2114920d1_8k.htm</File>
    <File>incy-20210504.xsd</File>
    <File>incy-20210504_lab.xml</File>
    <File>incy-20210504_pre.xml</File>
    <File>tm2114920d1_ex99-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm2114920d1_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2114920d1_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "incy-20210504_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "incy-20210504_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "incy-20210504.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "incy",
   "nsuri": "http://incyte.com/20210504",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2114920d1_8k.htm",
      "contextRef": "From2021-05-04to2021-05-04",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://incyte.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2114920d1_8k.htm",
      "contextRef": "From2021-05-04to2021-05-04",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r9",
      "r11",
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r10": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r11": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r12": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r13": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r14": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r15": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r16": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001104659-21-060485-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-21-060485-xbrl.zip
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M3DK3Q'R4[.=@UY1=]K$Z7QM.*JF'?P%02P,$%     @ %3FD4H$J@('^"@
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M0QP"+^BHH/&3BD(ZK+Q_YI&G;YQN689%/O]=V%HI0.>6'\!FDQM#%! O=F<
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M -(&-5"W;-T=/VH%)OES(^YU\:  -FN&UT4,'UDN*(J J3Y-P"_ /R/2@VG
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M5?PK0L@%.?1>G(@/%39?4XTJ;!8>7Q=('^C]WZ!-VM/<&C2R#F@;P M=8!+
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M =UE&,-CP(DZ1@L 7>## 6SW\(RBEW<4N3<;.R>#]I@C-+IF7; $&3*VRLF
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MC0=W!#T#Y PH(3":"1^&+UW,X)E\2_BD4U\/BAI'-Q^7%GE7EX6ME3"UT0_
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M2P$"% ,4    "  5.:12Y^K/23\#  "*#   $0              @ $
M:6YC>2TR,#(Q,#4P-"YX<V102P$"% ,4    "  5.:12@2J @?X*  #@AP
M%0              @ %N P  :6YC>2TR,#(Q,#4P-%]L86(N>&UL4$L! A0#
M%     @ %3FD4KQU4\=5!P  ,5D  !4              ( !GPX  &EN8WDM
M,C R,3 U,#1?<')E+GAM;%!+ 0(4 Q0    ( !4YI%(HJ\R:01$  +1A   2
M              "  2<6  !T;3(Q,30Y,C!D,5\X:RYH=&U02P$"% ,4
M"  5.:12-6^-F)%,   L%0, %@              @ &8)P  =&TR,3$T.3(P
C9#%?97@Y.2TQ+FAT;5!+!08     !0 % $D!  !==      !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
